Risedronate
Risedronate is a pyridinyl bisphosphonate. It is licensed for prevention and treatment of both postmenopausal and corticosteroid-induced osteoporosis.
Typical dosage regimens include: (1)
Paget's disease of bone: 30 mg orally daily for 2 months. The course may be repeated if necessary after at least 2 months.
Treatment of postmenopausal osteoporosis to reduce risk of vertebral or hip fractures: (female) 5 mg orally daily, alternatively 35 mg once weekly.
Prevention of osteoporosis (including corticosteroid-induced osteoporosis) in postmenopausal women: (female) 5 mg orally daily.
Treatment of osteoporosis in men at high risk of fractures: 35 mg orally once weekly.
Risedronate can also be given at a dose of 150mg once a month
Reference
- NICE: BNF. Drugs (Risedronate sodium). Online, 2026.
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.